Patient Confidence and Information Preferences During the Treatment Decision-making Process: Results From a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and Israel
CONCLUSION: Over half of patients felt very confident in their latest treatment decision; however, patients reported not routinely receiving important treatment effectiveness information. Addressing the discrepancies between information that patients receive and consider important may enhance confidence in decision-making.PMID:36967243 | DOI:10.1016/j.clml.2023.02.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2023 Category: Cancer & Oncology Authors: Ulf-Henrik Mellqvist H Tilman Steinmetz Aurore Perrot Erik Aerts Paul Williams Ana Vallejo Kate Morgan Ananda Plate Ana Mar ía Rodríguez-Leboeuf Renaud Desgraz Eva Hellqvist Franck Lucy De Costa Alessandra Brescianini Heinz Ludwig Source Type: research
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
CONCLUSION: Teclistamab showed significantly improved effectiveness versus PC on all outcomes, highlighting its clinical benefit in patients with TCE RRMM and limited treatment options.PMID:36967244 | DOI:10.1016/j.clml.2023.02.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2023 Category: Cancer & Oncology Authors: Mar ía-Victoria Mateos Ajai Chari Saad Z Usmani Hartmut Goldschmidt Katja Weisel Keqin Qi Anil Londhe Sandhya Nair Xiwu Lin Lixia Pei Eric Ammann Rachel Kobos Jennifer Smit Trilok Parekh Alexander Marshall Mary Slavcev Philippe Moreau Source Type: research
Patient Confidence and Information Preferences During the Treatment Decision-making Process: Results From a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and Israel
CONCLUSION: Over half of patients felt very confident in their latest treatment decision; however, patients reported not routinely receiving important treatment effectiveness information. Addressing the discrepancies between information that patients receive and consider important may enhance confidence in decision-making.PMID:36967243 | DOI:10.1016/j.clml.2023.02.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2023 Category: Cancer & Oncology Authors: Ulf-Henrik Mellqvist H Tilman Steinmetz Aurore Perrot Erik Aerts Paul Williams Ana Vallejo Kate Morgan Ananda Plate Ana Mar ía Rodríguez-Leboeuf Renaud Desgraz Eva Hellqvist Franck Lucy De Costa Alessandra Brescianini Heinz Ludwig Source Type: research
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
CONCLUSION: Teclistamab showed significantly improved effectiveness versus PC on all outcomes, highlighting its clinical benefit in patients with TCE RRMM and limited treatment options.PMID:36967244 | DOI:10.1016/j.clml.2023.02.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2023 Category: Cancer & Oncology Authors: Mar ía-Victoria Mateos Ajai Chari Saad Z Usmani Hartmut Goldschmidt Katja Weisel Keqin Qi Anil Londhe Sandhya Nair Xiwu Lin Lixia Pei Eric Ammann Rachel Kobos Jennifer Smit Trilok Parekh Alexander Marshall Mary Slavcev Philippe Moreau Source Type: research
Patient Confidence and Information Preferences During the Treatment Decision-making Process: Results From a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and Israel
CONCLUSION: Over half of patients felt very confident in their latest treatment decision; however, patients reported not routinely receiving important treatment effectiveness information. Addressing the discrepancies between information that patients receive and consider important may enhance confidence in decision-making.PMID:36967243 | DOI:10.1016/j.clml.2023.02.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2023 Category: Cancer & Oncology Authors: Ulf-Henrik Mellqvist H Tilman Steinmetz Aurore Perrot Erik Aerts Paul Williams Ana Vallejo Kate Morgan Ananda Plate Ana Mar ía Rodríguez-Leboeuf Renaud Desgraz Eva Hellqvist Franck Lucy De Costa Alessandra Brescianini Heinz Ludwig Source Type: research
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
CONCLUSION: Teclistamab showed significantly improved effectiveness versus PC on all outcomes, highlighting its clinical benefit in patients with TCE RRMM and limited treatment options.PMID:36967244 | DOI:10.1016/j.clml.2023.02.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2023 Category: Cancer & Oncology Authors: Mar ía-Victoria Mateos Ajai Chari Saad Z Usmani Hartmut Goldschmidt Katja Weisel Keqin Qi Anil Londhe Sandhya Nair Xiwu Lin Lixia Pei Eric Ammann Rachel Kobos Jennifer Smit Trilok Parekh Alexander Marshall Mary Slavcev Philippe Moreau Source Type: research
Patient Confidence and Information Preferences During the Treatment Decision-making Process: Results From a Large Multiple Myeloma Patient Survey Across 12 Countries in Europe and Israel
CONCLUSION: Over half of patients felt very confident in their latest treatment decision; however, patients reported not routinely receiving important treatment effectiveness information. Addressing the discrepancies between information that patients receive and consider important may enhance confidence in decision-making.PMID:36967243 | DOI:10.1016/j.clml.2023.02.010 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2023 Category: Cancer & Oncology Authors: Ulf-Henrik Mellqvist H Tilman Steinmetz Aurore Perrot Erik Aerts Paul Williams Ana Vallejo Kate Morgan Ananda Plate Ana Mar ía Rodríguez-Leboeuf Renaud Desgraz Eva Hellqvist Franck Lucy De Costa Alessandra Brescianini Heinz Ludwig Source Type: research
Comparative Efficacy of Teclistamab Versus Physician's Choice of Therapy in the Long-term Follow-up of APOLLO, POLLUX, CASTOR, and EQUULEUS Clinical Trials in Patients With Triple-class Exposed Relapsed or Refractory Multiple Myeloma
CONCLUSION: Teclistamab showed significantly improved effectiveness versus PC on all outcomes, highlighting its clinical benefit in patients with TCE RRMM and limited treatment options.PMID:36967244 | DOI:10.1016/j.clml.2023.02.006 (Source: Clinical Lymphoma and Myeloma)
Source: Clinical Lymphoma and Myeloma - March 26, 2023 Category: Cancer & Oncology Authors: Mar ía-Victoria Mateos Ajai Chari Saad Z Usmani Hartmut Goldschmidt Katja Weisel Keqin Qi Anil Londhe Sandhya Nair Xiwu Lin Lixia Pei Eric Ammann Rachel Kobos Jennifer Smit Trilok Parekh Alexander Marshall Mary Slavcev Philippe Moreau Source Type: research
Monoclonal Gammopathy of Undetermined Significance: A Comprehensive Review
This study aimed to conduct a critical review to update knowledge regarding the pathophysiology, risk factors, clinical features, diagnostic protocols, complications, and current and novel treatments for MGUS. We recommend a multidisciplinary approach to manage MGUS due to the complexity of the illness's etiology, diagnosis, and therapy. This comprehensive review also highlights future prospects, such as developing screening protocols for at-risk populations, prevention of disease progression by early diagnosis through genome-wide association studies, and management using Daratumumab and NSAIDs.PMID:36966041 | DOI:10.1016/...
Source: Clinical Lymphoma and Myeloma - March 25, 2023 Category: Cancer & Oncology Authors: Jasneet Kaur Sai Sudha Valisekka Maha Hameed Pushyami Satya Bandi Samyukta Varma Chibuzor Joseph Onwughalu Hany Ibrahim Himani Mongia Source Type: research
SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML)
Clin Lymphoma Myeloma Leuk. 2023 Feb 25:S2152-2650(23)00072-1. doi: 10.1016/j.clml.2023.02.008. Online ahead of print.ABSTRACTTyrosine kinase inhibitor (TKI) discontinuation, also known as treatment-free remission (TFR) is currently one of the main goals of chronic myeloid leukemia (CML) therapy. TKI discontinuation should be considered in eligible patients for several reasons. Specifically, TKI therapy is associated with reduced quality of life, long-term side effects, and a heavy financial burden on both the patients and society. TKI discontinuation is a particularly important goal for younger patients diagnosed with CML...
Source: Clinical Lymphoma and Myeloma - March 18, 2023 Category: Cancer & Oncology Authors: Sherrie Mikhaeel Ehab Atallah Source Type: research
SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML)
Clin Lymphoma Myeloma Leuk. 2023 Feb 25:S2152-2650(23)00072-1. doi: 10.1016/j.clml.2023.02.008. Online ahead of print.ABSTRACTTyrosine kinase inhibitor (TKI) discontinuation, also known as treatment-free remission (TFR) is currently one of the main goals of chronic myeloid leukemia (CML) therapy. TKI discontinuation should be considered in eligible patients for several reasons. Specifically, TKI therapy is associated with reduced quality of life, long-term side effects, and a heavy financial burden on both the patients and society. TKI discontinuation is a particularly important goal for younger patients diagnosed with CML...
Source: Clinical Lymphoma and Myeloma - March 18, 2023 Category: Cancer & Oncology Authors: Sherrie Mikhaeel Ehab Atallah Source Type: research
SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML)
Clin Lymphoma Myeloma Leuk. 2023 Feb 25:S2152-2650(23)00072-1. doi: 10.1016/j.clml.2023.02.008. Online ahead of print.ABSTRACTTyrosine kinase inhibitor (TKI) discontinuation, also known as treatment-free remission (TFR) is currently one of the main goals of chronic myeloid leukemia (CML) therapy. TKI discontinuation should be considered in eligible patients for several reasons. Specifically, TKI therapy is associated with reduced quality of life, long-term side effects, and a heavy financial burden on both the patients and society. TKI discontinuation is a particularly important goal for younger patients diagnosed with CML...
Source: Clinical Lymphoma and Myeloma - March 18, 2023 Category: Cancer & Oncology Authors: Sherrie Mikhaeel Ehab Atallah Source Type: research
SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML)
Clin Lymphoma Myeloma Leuk. 2023 Feb 25:S2152-2650(23)00072-1. doi: 10.1016/j.clml.2023.02.008. Online ahead of print.ABSTRACTTyrosine kinase inhibitor (TKI) discontinuation, also known as treatment-free remission (TFR) is currently one of the main goals of chronic myeloid leukemia (CML) therapy. TKI discontinuation should be considered in eligible patients for several reasons. Specifically, TKI therapy is associated with reduced quality of life, long-term side effects, and a heavy financial burden on both the patients and society. TKI discontinuation is a particularly important goal for younger patients diagnosed with CML...
Source: Clinical Lymphoma and Myeloma - March 18, 2023 Category: Cancer & Oncology Authors: Sherrie Mikhaeel Ehab Atallah Source Type: research
SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML)
Clin Lymphoma Myeloma Leuk. 2023 Feb 25:S2152-2650(23)00072-1. doi: 10.1016/j.clml.2023.02.008. Online ahead of print.ABSTRACTTyrosine kinase inhibitor (TKI) discontinuation, also known as treatment-free remission (TFR) is currently one of the main goals of chronic myeloid leukemia (CML) therapy. TKI discontinuation should be considered in eligible patients for several reasons. Specifically, TKI therapy is associated with reduced quality of life, long-term side effects, and a heavy financial burden on both the patients and society. TKI discontinuation is a particularly important goal for younger patients diagnosed with CML...
Source: Clinical Lymphoma and Myeloma - March 18, 2023 Category: Cancer & Oncology Authors: Sherrie Mikhaeel Ehab Atallah Source Type: research
SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML)
Clin Lymphoma Myeloma Leuk. 2023 Feb 25:S2152-2650(23)00072-1. doi: 10.1016/j.clml.2023.02.008. Online ahead of print.ABSTRACTTyrosine kinase inhibitor (TKI) discontinuation, also known as treatment-free remission (TFR) is currently one of the main goals of chronic myeloid leukemia (CML) therapy. TKI discontinuation should be considered in eligible patients for several reasons. Specifically, TKI therapy is associated with reduced quality of life, long-term side effects, and a heavy financial burden on both the patients and society. TKI discontinuation is a particularly important goal for younger patients diagnosed with CML...
Source: Clinical Lymphoma and Myeloma - March 18, 2023 Category: Cancer & Oncology Authors: Sherrie Mikhaeel Ehab Atallah Source Type: research
